CLINICAL TRIALS PROFILE FOR GALANTAMINE HYDROBROMIDE
✉ Email this page to a colleague
All Clinical Trials for galantamine hydrobromide
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00077727 ↗ | A Study of the Effectiveness and Safety of Galantamine Hydrobromide on Cognitive Impairment in Patients With Schizophrenia. | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 3 | 2003-03-01 | The purpose of this study is to determine if adding extended-release galantamine hydrobromide, compared with adding placebo, to current atypical antipsychotic therapy is well tolerated and effective in improving cognitive impairment in patients with schizophrenia. |
| NCT00216502 ↗ | A Study of the Safety and Effectiveness of Galantamine in Patients With Alzheimer's Disease | Completed | Janssen-Cilag S.p.A. | Phase 3 | 2001-08-01 | The purpose of this study is to evaluate the long-term efficacy and safety of galantamine in patients with Alzheimer's disease. |
| NCT00216515 ↗ | The Efficacy of Galantamine on the Attention and the Frontal Function of the Patients With Dementia of Alzheimer Type | Completed | Janssen Korea, Ltd., Korea | Phase 4 | 2004-03-01 | The purpose of this study is to assess the efficacy of galantamine on the attention of patients with Alzheimer's Disease, how an improvement of attention of Alzheimer's Disease patients affects their activities of daily living, and the global benefit of galantamine. |
| NCT00216593 ↗ | Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Controlled Study | Completed | Janssen Pharmaceutica N.V., Belgium | Phase 3 | 2003-12-01 | The purpose of this study is to assess the effectiveness and safety of galantamine hydrobromide treatment in patients with severe Alzheimer's disease. |
| NCT00236431 ↗ | A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 3 | 2001-05-01 | The purpose of this study is to evaluate the efficacy and safety of galantamine treatment in patients with mild cognitive impairment. |
| NCT00236574 ↗ | A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 3 | 2001-05-01 | The purpose of this study is to evaluate the efficacy and safety of galantamine treatment in patients with mild cognitive impairment. |
| NCT00240695 ↗ | A Follow-up Study to Assess Safety and Tolerability of Galantamine Treatment in Individuals With Mild Cognitive Impairment | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 3 | 2003-05-01 | The purpose of this follow-up study is to assess the long-term safety and tolerability of galantamine in individuals with mild cognitive impairment who participated in a previous study with galantamine |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for galantamine hydrobromide
Condition Name
Clinical Trial Locations for galantamine hydrobromide
Trials by Country
Clinical Trial Progress for galantamine hydrobromide
Clinical Trial Phase
Clinical Trial Sponsors for galantamine hydrobromide
Sponsor Name
